NVO Novo Nordisk A/S
- Official Name: Novo Nordisk A/S
- Headquarters: 800 Scudders Mill Road, PLAINSBORO, NJ 08536, US
- CEO: Lars Jorgensen
- Website: novonordisk.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-15 | 1 | Lost by 2.564 | (1.182) - 1.382 | ||
| 2025-07-15 | 1R | Lost by 1.938 | (2.019) - (0.081) | ||
| 2025-07-16 | 1R | Lost by 1.386 | (0.444) - 0.942 | ||
| 2025-07-22 | 2 | Lost by 3.178 | (2.159) - 1.019 | ||
| 2025-07-29 | 3 | Lost by 14.791 | (13.934) - 0.857 | ||
| 2025-08-05 | 4 | Won by 15.265 TOTW | 16.343 - 1.078 | ||
| 2025-08-12 | 5 | Won by 8.446 | 9.709 - 1.263 | ||
| 2025-08-19 | 6 | Won by 5.511 TOTW | 10.297 - 4.786 | ||
| 2025-08-26 | 7 | Won by 1.063 | 0.879 - (0.184) | ||
| 2025-09-02 | 8 | Lost by 0.650 | 1.874 - 2.524 | ||
| 2025-09-09 | 9 | Lost by 0.558 | (4.801) - (4.243) | ||
| 2025-09-16 | 10 | Won by 5.861 TOTW | 6.228 - 0.367 | ||
| 2025-09-23 | 11 | Won by 5.538 | 3.997 - (1.541) | ||
| 2025-09-30 | 12 | Lost by 11.395 | (7.175) - 4.220 | ||
| 2025-10-07 | 13 | Won by 5.969 | 5.887 - (0.082) | ||
| 2025-10-14 | 14 | Lost by 8.376 | (4.073) - 4.303 | ||
| 2025-10-21 | 15 | Lost by 2.487 | (3.541) - (1.054) |
Latest News
SeekingAlpha - 2026-08-31
Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs
Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more a...
SeekingAlpha - 2026-08-31
Novo Nordisk: Why The Price Remains Stubbornly Low (Rating Downgrade)
Novo Nordisk (NVO) is under pressure after Q2 2026 results: Wegovy pill gains but sales missed.
SeekingAlpha - 2026-08-31
Hims & Hers: A Healthcare Behemoth In The Making
Hims & Hers Health is building a vertically integrated consumer health distribution platform. Read why I am bullish about HIMS stock right now.
SeekingAlpha - 2026-08-27
Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More
Biohaven Ltd. maintains a Buy rating, driven by pivotal trial progress in protein degraders and a key licensing deal for its Kv7 platform. Click here ...
Benzinga - 2026-08-27
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transac...
Show more
Benzinga - 2026-08-26
Boston Scientific Reports Global Disruption After Cybersecurity Incident
Benzinga - 2026-08-26
Eli Lilly Announces Results From Real-World Study Of Overweight Or Obese Adults Over 55 Indicating That Staying On Zepbound For Weight Management Lowered Healthcare Costs Over Time
SeekingAlpha - 2026-08-24
Novo Nordisk: Don't Ignore This Dirt-Cheap Buying Opportunity
SeekingAlpha - 2026-08-22
Eli Lilly: Shaking Off Competition From The Dethroned Novo Nordisk
SeekingAlpha - 2026-08-21
Novo Nordisk: The Pill That Could Close The Gap With Lilly
Benzinga - 2026-08-21
10 Health Care Stocks Whale Activity In Today’s Session
SeekingAlpha - 2026-08-19
Novo Nordisk: The Best Value In Pharma
Benzinga - 2026-08-19
Hims & Hers Rejects Privacy Allegations While Promising Expanded Patient Access
Benzinga - 2026-08-19
'Novo Nordisk Starts Testing Lower-Doses of Its Wegovy Weight-Loss Pills' - WSJ
Benzinga - 2026-08-17
4 Health Care Stocks With Whale Alerts In Today’s Session
SeekingAlpha - 2026-08-12
I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)
SeekingAlpha - 2026-08-12
The Market Is (Still) Underestimating Novo Nordisk
Benzinga - 2026-08-11
Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst
Benzinga - 2026-08-11
Novo Nordisk Announces U.S. Availability Of Awiqli, Its First Once-Weekly Basal Insulin For Adults With Type 2 Diabetes
Benzinga - 2026-08-10
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule
SeekingAlpha - 2026-08-07
Eli Lilly: 'Strong Buy' On Retatrutide Obesity Drug And EBGLYSS Maintenance Label Expansion
SeekingAlpha - 2026-08-07
Reassessing Inflammation's Link To Cardiovascular Risk
SeekingAlpha - 2026-08-07
Novo Nordisk: Dismal Q2 Earnings, Operational Frailties Warrant Rating Downgrade
Benzinga - 2026-08-07
Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients
SeekingAlpha - 2026-08-06
Novo Nordisk: The Market Has Lost Its Mind, Too Cheap To Ignore
Benzinga - 2026-08-06
Novo Nordisk Scores Major Court Win, Dutch Judge Halts Compounded Semaglutide Nasal Spray
Benzinga - 2026-08-06
Bank of America Spends $250 Million a Year on Ozempic and Other GLP-1 Drugs, CEO Calls It 'a Good Investment'
Benzinga - 2026-08-06
Amazon Pharmacy Start Delivery GLP-1 Medications To Eligible Medicare Patients For $50 Per Month
SeekingAlpha - 2026-08-05
Novo Nordisk A/S (NOVO:CA) Q2 2026 Earnings Call Transcript
SeekingAlpha - 2026-08-05
Novo Nordisk A/S 2026 Q2 - Results - Earnings Call Presentation
SeekingAlpha - 2026-08-05
Novo Nordisk: Opportunistically Adding To A Long-Term Winner (Q2 Review)
Benzinga - 2026-08-05
CVS Health Retools Its Weight Management Program To Make It Easier For Eligible Adults To Access Clinical Care, Navigate Medication Costs And Get Ongoing Support For GLP-1 Therapy
SeekingAlpha - 2026-08-04
Lower Risk And Higher Total Returns: My 1-Year Review
Benzinga - 2026-08-04
Novo Nordisk Q2 Adj. EPS $0.96 Beats $0.81 Estimate, Sales $12.209B Beat $11.350B Estimate
Benzinga - 2026-08-04
Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks
SeekingAlpha - 2026-08-04
OPKO Health: Mazdutide And MDX-2201 Could Change Everything
Benzinga - 2026-08-04
Novo Nordisk Reports DKK 6.3B Non-Recurring, Non-Cash Impairment Charges In Q2 Related To Intangible Pipeline Assets
SeekingAlpha - 2026-08-04
SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For August 2026
Benzinga - 2026-08-03
6 Health Care Stocks Whale Activity In Today’s Session
SeekingAlpha - 2026-08-01
SpaceX's First Earnings Post IPO
SeekingAlpha - 2026-07-31
Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run
Benzinga - 2026-07-31
Why Is BioAge Labs Stock Sinking Friday?
Benzinga - 2026-07-31
Novo Nordisk Says Anti-Inflammatory Drug Trial Fails to Cut Cardiovascular Risk in High Risk Patients
Benzinga - 2026-07-31
Novo Nordisk Announces Ziltivekimab Did Not Translate Into Major Adverse Cardiovascular Events Risk Reduction During Phase 3 Trial In Patients With Atherosclerotic Cardiovascular Disease
SeekingAlpha - 2026-07-29
Novo Nordisk: Too Late For A Great Opportunity
Benzinga - 2026-07-27
4 Health Care Stocks Whale Activity In Today’s Session
SeekingAlpha - 2026-07-27
Novo Nordisk: Sensitivity Analysis Of Oral Wegovy's Gross Profits Supports Modest Buy
SeekingAlpha - 2026-07-27
Novo Nordisk Remains A Generational Buying Opportunity Ahead Of Q2 Earnings
SeekingAlpha - 2026-07-26
Novo Nordisk: Initiating Buy, Calling The Bottom
SeekingAlpha - 2026-07-26
Earn 10-15% Potential Income: Monthly Options Series (Aug. 2026)
SeekingAlpha - 2026-07-26
Novo Nordisk: Mr. Market Is Pricing In Success, But It's Too Early To Bank On That
Benzinga - 2026-07-24
The Wall Street Journal Reported Earlier, Novo Nordisk Filed Preliminary Injunction Request In U.S. Court To Halt Eli Lilly GLP-1 Weight-Loss Drug Advertising During Lawsuit Proceedings
Benzinga - 2026-07-23
Eli Lilly Reports Topline Results From TRIUMPH-2 And TRIUMPH-3 Phase 3 Trials Evaluating Retatrutide; Treatment Met Primary Endpoint, With Substantial Weight Loss In Adults With Obesity
SeekingAlpha - 2026-07-22
Wall Street Breakfast Podcast: Super Micro Heats Up
Benzinga - 2026-07-21
Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Weight Loss Drug Advertising
Benzinga - 2026-07-21
Novo Nordisk Takes Legal Action Against Eli Lilly To Stop Multiple Misleading National GLP-1 Advertising Campaigns
SeekingAlpha - 2026-07-20
Novo Nordisk's Rally Has Room To Run Driven By Oral Wegovy's Momentum
SeekingAlpha - 2026-07-18
AI Bubble Risks Make Dividend Stocks Attractive Again
SeekingAlpha - 2026-07-17
Where To Invest Now In AI, Biotech, Small Caps, And Gold
SeekingAlpha - 2026-07-17
Novo Nordisk: The Oral Wegovy Promise
Benzinga - 2026-07-17
Reported Earlier: 'India approves Novo Nordisk's obesity drug Wegovy for fatty liver disease' - Reuters
SeekingAlpha - 2026-07-16
Europe's Other Story: 5 Reasons The Continent's Equities Are Worth A Closer Look
Fintel - 2026-07-16
JYSKE BANK Downgrades Novo Nordisk A (NVO)
Benzinga - 2026-07-16
Medicare's $50 Weight-Loss Drug Window Opens In July: What Smart Enrollees Do Before 2027
Yahoo - 2026-07-15
Novo Nordisk (CPSE:NOVO B) Stock Fair Value Edges Higher As Analysts Rework Growth Assumptions
Yahoo - 2026-07-15
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal
Yahoo - 2026-07-15
Lilly's Obesity Pill Trails Wegovy
Yahoo - 2026-07-15
Sector Update: Healthcare Stocks Advance Late Afternoon
Yahoo - 2026-07-15
NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart
Yahoo - 2026-07-15
Sector Update: Healthcare Stocks Advance in Afternoon Trading
Yahoo - 2026-07-15
Novo Nordisk Gets EU Approval for Wegovy Pill for Weight Management
Yahoo - 2026-07-15
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
Yahoo - 2026-07-15
European Equities Traded in the US as American Depositary Receipts Advance Wednesday
Benzinga - 2026-07-15
Wegovy Pill in Europe - Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug
Yahoo - 2026-07-15
Cellular Intelligence Expands Leadership Team with Seasoned AI and Biotech Industry Executives
Benzinga - 2026-07-15
Novo Nordisk Receives European Commission's Marketing Authorization For Wegovy Pill To Treat Adults With Obesity
Yahoo - 2026-07-15
How Microsoft (MSFT) Is Deepening Its Enterprise AI Moat With a $2.5 Billion Customer Deployment Initiative
Yahoo - 2026-07-15
2 Beaten-Down GLP-1 Stocks to Buy on the Dip
Yahoo - 2026-07-14
Novo Nordisk (CPSE:NOVO B) Reports Fresh Hemophilia Trial Wins In Adults And Children
Yahoo - 2026-07-14
Novo Nordisk signs pact to assess semaglutide implant
Yahoo - 2026-07-14
Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?
SeekingAlpha - 2026-07-13
How To Build A $50,000 Dividend Portfolio In Today's Market
Benzinga - 2026-07-13
Novo Nordisk Shares Encouraging Long-Term Data From Hemophilia Program
SeekingAlpha - 2026-07-09
Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry
SeekingAlpha - 2026-07-09
Novo Nordisk: Why I Don't Think The Story Is Broken
SeekingAlpha - 2026-07-08
Fundsmith Equity Fund: H1 2026 Sales
SeekingAlpha - 2026-07-07
If I Could Only Buy Two High-Yield Stocks In July 2026
SeekingAlpha - 2026-07-07
Novo Nordisk Loses Its Edge, And I'm Downgrading
SeekingAlpha - 2026-07-07
My (Still) 21% Yielding Portfolio Update
SeekingAlpha - 2026-07-07
Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade
Benzinga - 2026-07-07
Vivani Medical To Allow Novo Nordisk To Evaluate NPM-139, The Company’s Semaglutide Drug Implant
SeekingAlpha - 2026-07-06
Boston Scientific: The Time Has Come To Catch This Falling Knife
Benzinga - 2026-07-06
AdaptHealth Flags Material Breach After Threat Actor Accessed Patient Management Systems
SeekingAlpha - 2026-07-06
My Top 5 Pharma Stocks Wall Street Ignores
Benzinga - 2026-07-05
Warren Says Trump's Law Pushed 2 Million-Plus Children Off Medicaid, CHIP Across States
SeekingAlpha - 2026-07-04
Novo Nordisk: The Stock Price Is Only Beginning To Catch Up With Business Fundamentals
SeekingAlpha - 2026-07-03
SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For July 2026
SeekingAlpha - 2026-07-03
HIMS Breakout Signals Structural Business Transformation
SeekingAlpha - 2026-07-02
Ascendis Pharma: Behind The Stock Surge
SeekingAlpha - 2026-06-30
Like My Stock Portfolio, My Bullish Options Portfolio Crushed The Benchmarks
SeekingAlpha - 2026-06-30
Building A $100,000 Dividend Portfolio With SCHD And July's Top High-Yield Picks
SeekingAlpha - 2026-06-30
Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate
Benzinga - 2026-06-30
Getting Wegovy Or Zepbound Through Medicare? Here's What Patients Need To Know Before Coverage Rolls Out Wednesday
SeekingAlpha - 2026-06-29
Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It
SeekingAlpha - 2026-06-28
My Top 10 High-Yield Picks For July 2026: One Yields More Than 13%
SeekingAlpha - 2026-06-26
Eli Lilly: Exceptional Pipeline, Less Attractive Entry Point (Rating Downgrade)
SeekingAlpha - 2026-06-26
Novo Nordisk: 3 Key Reasons The 'Buy The Dip' Thesis Is Flawed
SeekingAlpha - 2026-06-25
Ozempic Sat Unused For Decades Because Invention Is Not Enough
SeekingAlpha - 2026-06-24
Undercovered Dozen: Blue Owl, IBM, Quantum Computing, Fiserv And More
SeekingAlpha - 2026-06-24
Novo Nordisk: A Strong Yield And Continued Growth
Benzinga - 2026-06-24
White House Denies Report Linking Trump To Eli Lilly's Experimental Obesity Treatment: 'Not For The President'
SeekingAlpha - 2026-06-23
Healthcare's Quiet Comeback: Innovation, Obesity Drugs And New Opportunities
SeekingAlpha - 2026-06-23
Novo Nordisk: The Selloff Looks Like A Gift, And I'm Buying
Benzinga - 2026-06-22
Novo Nordisk Stock Is Surging Monday: What's Driving The Action?
Benzinga - 2026-06-22
CVS Pharmacy Announces New GLP-1 Offerings, Including Expanded Pharmacy Support And A New $49 MinuteClinic Virtual Visit That Connects Eligible Adults With Licensed Clinicians
Benzinga - 2026-06-22
Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model
Benzinga - 2026-06-18
Hims & Hers Stock Jumps After Barclays Raises Price Target
SeekingAlpha - 2026-06-18
My Top 5 Dividend Picks For June
Benzinga - 2026-06-17
Novo Nordisk Data Breach: Hackers Claim To Have Stolen Drug Research, Trial Data And AI Models
Benzinga - 2026-06-17
7 Health Care Stocks With Whale Alerts In Today's Session
SeekingAlpha - 2026-06-17
Eli Lilly: Pharma With Unstoppable Momentum Targets Pain With Latest M&A Deal
Benzinga - 2026-06-17
Reported June 16, 2026: 'Hacking Group Claims Major Hack Of Novo Nordisk And Attempted $25 Million Extortion' - Reuters News
SeekingAlpha - 2026-06-16
Novo Nordisk: A Fallen Leader Trading At Fair Value, Not A Bargain
SeekingAlpha - 2026-06-16
Hims & Hers Enters A New Phase
Benzinga - 2026-06-16
Reported Earlier: 'Novo Nordisk to seek approval soon to sell Wegovy pill in China' - Reuters
Benzinga - 2026-06-15
Doctors Warn Medicare's New Weight-Loss Drug Program Could Lead To A Rush Of Patients That Clinics May Struggle To Handle
SeekingAlpha - 2026-06-15
10 Dividend Growth Stocks: June 2026
SeekingAlpha - 2026-06-15
Novo Nordisk: The Danish Empire Strikes Back
SeekingAlpha - 2026-06-13
Novo Nordisk: Why The Wegovy Pill Doesn't Change My Thesis
SeekingAlpha - 2026-06-12
Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy
Benzinga - 2026-06-11
Novo Nordisk Advances Weight-Loss Portfolio With UK Approval Of Wegovy Tablet
Benzinga - 2026-06-11
Novo Nordisk Reports Unauthorized Access IT Security Incident; Core Business Operations Are Not Impacted, Some Personal Data Was Extracted
Benzinga - 2026-06-11
Wegovy Receives Medicines And Healthcare Products Regulatory Agency's Approval To Treat Obesity
SeekingAlpha - 2026-06-10
Viking Therapeutics: Drugs Are In The Pipeline, But Profitability Is Still Unproven
SeekingAlpha - 2026-06-10
Roche Vs. Pfizer: Obesity Week Presentations Deep Dive - What Investors Must Know
SeekingAlpha - 2026-06-08
Novo Nordisk: The Biggest Healthcare Bargain
Benzinga - 2026-06-08
Novo Nordisk Highlights Positive Weight-Loss Data Across Multiple Programs
SeekingAlpha - 2026-06-08
Wall Street Breakfast Podcast: Pfizer Chases Monthly Edge
Benzinga - 2026-06-08
Novo Nordisk CEO Hints Semaglutide Could Be More Than A Weight-Loss Drug: 'A Bit Of A Longevity Game'
SeekingAlpha - 2026-06-07
Novo Nordisk A/S (NOVO:CA) Discusses Obesity and Diabetes Portfolio Progress and Pill Launch Milestones at R&D Event Transcript
SeekingAlpha - 2026-06-05
Amgen: Time For An Upgrade? Yes, I Think So
Benzinga - 2026-06-04
8 Stocks Moving In Wednesday's After-Hours Session
Benzinga - 2026-06-04
4 Health Care Stocks With Whale Alerts In Today's Session
SeekingAlpha - 2026-06-04
SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For June 2026
Benzinga - 2026-06-04
Veru Strikes Clinical Supply Agreement With Novo Nordisk To Mull Combination Of Enobosarm With Wegovy
Benzinga - 2026-06-03
10 Health Care Stocks Whale Activity In Today's Session
SeekingAlpha - 2026-06-03
Novo Nordisk: Deeply Undervalued With A Return To Growth In 2027
SeekingAlpha - 2026-06-03
Wall Street Breakfast Podcast: Bitcoin's Great Withdrawal
SeekingAlpha - 2026-06-02
Madrigal Pharmaceuticals Could Become The Next Vertex
SeekingAlpha - 2026-06-01
Omeros: Launch Traction Encouraging, But Risk/Reward Looks Balanced (Initiating Hold)
SeekingAlpha - 2026-05-29
Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class
SeekingAlpha - 2026-05-28
Eli Lilly Expands Into Infectious Diseases, Retatrutide Adds Another Phase 3 Win
SeekingAlpha - 2026-05-28
Wall Street Underestimates Novo Nordisk's GLP-1 Comeback
Benzinga - 2026-05-28
CVS Expands GLP-1 Options For Members, Including The Reintroduction Of Zepbound As A Covered Medication
Benzinga - 2026-05-22
Novo Nordisk Gets European Commission Extension To Marketing Authorisation For Wegovy In EU To Add An Oral Formulation For Weight Management
SeekingAlpha - 2026-05-21
These Are The Upcoming Catalysts For Crispr Therapeutics Stock
SeekingAlpha - 2026-05-20
GoodRx: TrumpRx Exposes Legacy Moat Breach And Zero-Sum Strategy (Downgrade)
SeekingAlpha - 2026-05-20
Novo Nordisk: 2 Reasons To Buy This GLP-1 Giant
SeekingAlpha - 2026-05-19
Eli Lilly: Novo Nordisk Was Just A Warm-Up
Benzinga - 2026-05-19
Novo Nordisk To Unveil Data Showing Semaglutide Tackles The Liver Disease Crisis Affecting About 1 In 3 People Living With Overweight And Obesity Worldwide
Benzinga - 2026-05-19
Supreme Court Hands Major Blow To Big Pharma's Fight Against Biden-Era Medicare Drug Pricing Law
Benzinga - 2026-05-18
'Drug Companies Spurned by Supreme Court on Price Negotiation Law' - Bloomberg News
SeekingAlpha - 2026-05-18
Why Pfizer Stock Still Looks Deeply Undervalued In 2026
SeekingAlpha - 2026-05-15
Hims & Hers Health: The Stock Is On Sale, Buy It
SeekingAlpha - 2026-05-14
Novo Nordisk: The First Fruits Of Labor
SeekingAlpha - 2026-05-14
Hims & Hers Health Is Likely Dead Money
SeekingAlpha - 2026-05-14
Novo Nordisk: Why I Won't Upgrade
Benzinga - 2026-05-14
Trump's Drug Pricing Plan Gains Surprise Democratic Ally— Peter Welch Vows To 'Make It Happen'
Benzinga - 2026-05-13
Here's How Much $100 Invested In Novo Nordisk 15 Years Ago Would Be Worth Today
Benzinga - 2026-05-13
Novo Nordisk Highlights New Wegovy Pill Data
Benzinga - 2026-05-13
Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss
SeekingAlpha - 2026-05-13
April CPI Inflation: Brace For Margin Pressure
SeekingAlpha - 2026-05-13
Novo Nordisk: Why A P/E Of 13 Is A Value Trap, Not A Bargain
Benzinga - 2026-05-12
Novo Nordisk Presents New Wegovy Data Showing Strong Weight Loss, Fat Reduction
Benzinga - 2026-05-12
Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts
Benzinga - 2026-05-12
Novo Nordisk Says Wegovy Showed An Average 22.6% Weight Loss For Premenopausal Women With Obesity, With More Than 41% Achieving 25% Or More Weight Loss
Benzinga - 2026-05-11
Cellular Intelligence To Acquire Novo Nordisk's STEM-PD Parkinson's Cell Therapy Program; No Financial Terms Disclosed
Benzinga - 2026-05-10
Trump Admin Proposes New IVF Benefit To Expand Fertility CoverageThrough Employers
SeekingAlpha - 2026-05-10
Novo Nordisk: Flipping The Script
SeekingAlpha - 2026-05-07
Wall Street Lunch: DOJ, CFTC Investigate Suspicious $2.6B Oil Trades Tied To Iran Conflict Headlines
Benzinga - 2026-05-07
CMS To Offer Wegovy To Eligible Medicare Patients At $50 Monthly Copay Starting July 2026
Benzinga - 2026-05-07
Eli Lilly To Invest $4.5 Billion More In Indiana Manufacturing Sites
Benzinga - 2026-05-06
Earnings Scheduled For May 6, 2026
SeekingAlpha - 2026-05-06
Novo Nordisk: Mixed Q1 Does Not Break The Thesis, But Also Does Not Strengthen It
Benzinga - 2026-05-06
S&P 500, Nasdaq 100 Smash Records As AMD Jumps 16% On AI Hype: Stock Market Today
SeekingAlpha - 2026-05-06
Novo Nordisk: Misread Q1 Earnings, Mispriced Stock
Benzinga - 2026-05-06
Is Semi Mania Leading To A 2000-Style Crash? US-Iran Proposal Lifts Market, Pressures Oil
SeekingAlpha - 2026-05-06
Novo Nordisk A/S (NOVO:CA) Q1 2026 Earnings Call Transcript
Benzinga - 2026-05-06
Trump's Drug Pricing Deals Could Lead To $529 Billion Savings For The Economy Over The Decade: Report
Benzinga - 2026-05-06
'Novo Sees Generic Ozempic Delayed in China Until Next Year' - Bloomberg
Benzinga - 2026-05-06
Wegovy Pill Debut 'Fattens' Novo Nordisk's Profit Outlook
ChartMill - 2026-05-06
Record Highs, Punished Results, and One Very Consequential Apple Rumor
SeekingAlpha - 2026-05-06
Novo Nordisk A/S 2026 Q1 - Results - Earnings Call Presentation
Benzinga - 2026-05-06
Novo Nordisk Raises FY2026 Sales Guidance from $40.463B-$44.317B to $42.389B-$46.243B vs $45.440B Est
Benzinga - 2026-05-06
Novo Nordisk Q1 Adj. EPS $1.04 Beats $0.87 Estimate, Sales $15.173B Beat $11.130B Estimate
SeekingAlpha - 2026-05-05
Viking Therapeutics: Market Betting On Big Upside Through 2030
SeekingAlpha - 2026-05-05
SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For May 2026
Benzinga - 2026-05-05
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 15 Years
SeekingAlpha - 2026-05-05
AI Revolutionizing Biopharma: Faster, Better, Cheaper
SeekingAlpha - 2026-05-05
Novo Nordisk: My Q1 Preview And Why I'm Doubling Down
SeekingAlpha - 2026-05-05
Eli Lilly: No Big Gap To Competition
SeekingAlpha - 2026-05-04
Novo Nordisk: A Generational Buying Opportunity Ahead Of Q1 Earnings
Benzinga - 2026-05-04
GLP-1 Boom Sparks Potential 'Bubble Effect,' Shrinking Competition In Big Pharma, Warns Deloitte: 'The Question Is...'
Benzinga - 2026-05-01
S&P 500's Best‑Kept Secret: Why Healthcare Could Be 2026's Breakout Winner
Benzinga - 2026-05-01
10 Health Care Stocks With Whale Alerts In Today's Session
SeekingAlpha - 2026-05-01
Hims & Hers, Novo Nordisk: FDA GLP-1 Compounding Ruling May Actually Favor Hims
Benzinga - 2026-05-01
Eli Lilly Jumps As Earnings Beat Meets FDA Tightening Drug Compounding Rules
SeekingAlpha - 2026-05-01
Eli Lilly: Buying Opportunity Knocking On The Front Door Again (Rating Upgrade)
Benzinga - 2026-05-01
Novo Nordisk's Ozempic pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the US
Benzinga - 2026-05-01
GoodRx Providing Access To Novo Nordisk's Ozempic Pill At $149/Month
SeekingAlpha - 2026-05-01
Pfizer: Why You Should Double Down Into Q1
Benzinga - 2026-04-30
FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List; Finds No Clinical Need For Bulk Compounding Of These Drugs
SeekingAlpha - 2026-04-30
Novo Nordisk: Pricing Pressure And Falling Margins Make This A Value Trap (Q1 Earnings Preview)
Benzinga - 2026-04-30
Elizabeth Warren Calls Trump's '600%' Drug Price Claim Mathematically Impossible: 'His Promise Is As Empty As…'
Benzinga - 2026-04-29
Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth
SeekingAlpha - 2026-04-28
Wegovy's Early Lead To Narrow As Eli Lilly Prepares Foundayo Launch
Benzinga - 2026-04-28
'Canada Approves Its First Generic Version of Novo's Ozempic' - Bloomberg News
Benzinga - 2026-04-27
Prothena Announces Coramitug Amyloid Depleter Antibody Receives FDA's Fast Track Designation To Treat ATTR Amyloidosis With Cardiomyopathy
Benzinga - 2026-04-27
4 Health Care Stocks Whale Activity In Today's Session
SeekingAlpha - 2026-04-27
Regeneron: Catching Another Wind
ChartMill - 2026-04-27
Intel Resets the Clock on the Chip Sector and the Weekend Complicated Everything Else
SeekingAlpha - 2026-04-24
Eli Lilly: A Heavyweight Battle Isn't Won In Round 1
SeekingAlpha - 2026-04-24
Depressed Equities That May Be Worth Investigating Further
Benzinga - 2026-04-24
Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children
Benzinga - 2026-04-24
Novo Nordisk shares are trading higher after the company announced results of an oral semaglutide trial in children aged 10-17 years with type 2 diabetes.
SeekingAlpha - 2026-04-24
Abbott Laboratories: Buying A Healthcare Giant On Sale
Benzinga - 2026-04-23
Hims & Hers Positions Itself As Supply Anchor In Hormone Therapy Crunch
Benzinga - 2026-04-23
Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients
Benzinga - 2026-04-23
Novo Nordisk Oral Semaglutide In PIONEER TEENS Trial In Children 10–17 With Type 2 Diabetes Achieved 0.83% Blood Sugar Reduction Vs Placebo At 26 Weeks
SeekingAlpha - 2026-04-22
Novo Nordisk: Is The GLP‑1 Golden Age Already Behind It?
Benzinga - 2026-04-21
Amazon GLP-1 Program Pressures Hims & Hers Stock
Benzinga - 2026-04-21
Amazon One Medical Introduces Weight Management Program With Upfront GLP-1 Medication Costs
SeekingAlpha - 2026-04-19